- Home
- VRAR vs DYAI Comparison
VRAR vs DYAI Comparison
Compare VRAR & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- DYAI
- Stock Information
- Founded
- VRAR 2016
- DYAI 1979
- Country
- VRAR United States
- DYAI United States
- Employees
- VRAR N/A
- DYAI N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRAR Technology
- DYAI Health Care
- Exchange
- VRAR Nasdaq
- DYAI Nasdaq
- Market Cap
- VRAR 29.1M
- DYAI 30.2M
- IPO Year
- VRAR 2021
- DYAI 2004
- Fundamental
- Price
- VRAR $1.13
- DYAI $0.92
- Analyst Decision
- VRAR Strong Buy
- DYAI Strong Buy
- Analyst Count
- VRAR 1
- DYAI 1
- Target Price
- VRAR $2.62
- DYAI $3.00
- AVG Volume (30 Days)
- VRAR 137.0K
- DYAI 100.8K
- Earning Date
- VRAR 11-13-2025
- DYAI 11-12-2025
- Dividend Yield
- VRAR N/A
- DYAI N/A
- EPS Growth
- VRAR N/A
- DYAI N/A
- EPS
- VRAR N/A
- DYAI N/A
- Revenue
- VRAR $9,488,209.00
- DYAI $3,342,195.00
- Revenue This Year
- VRAR $15.29
- DYAI $18.18
- Revenue Next Year
- VRAR $44.54
- DYAI $87.65
- P/E Ratio
- VRAR N/A
- DYAI N/A
- Revenue Growth
- VRAR 16.60
- DYAI N/A
- 52 Week Low
- VRAR $0.50
- DYAI $0.71
- 52 Week High
- VRAR $7.00
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- VRAR 33.19
- DYAI 39.44
- Support Level
- VRAR $1.39
- DYAI $0.88
- Resistance Level
- VRAR $1.43
- DYAI $0.98
- Average True Range (ATR)
- VRAR 0.13
- DYAI 0.08
- MACD
- VRAR -0.04
- DYAI -0.02
- Stochastic Oscillator
- VRAR 12.90
- DYAI 18.40
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.